VIVES is a multi-sector fund that invests in projects with a positive societal impact
ViroVet is a pioneering company dedicated to the development of innovative and disruptive technologies for the control of viral diseases in livestock. It develops antiviral drugs for complex...
Botalys has developed a technology (vertical farming) that allows to produce rare plants and ingredients for the food supplement, cosmetics and pharmacy industries. Vertical farming allows them to...
Founded in 2013 by Dr. Denis Dufrane and Dr. Jean-François Pollet, Novadip Biosciences is a spin-off from the University of Louvain (UCLouvain) and Saint-Luc University Clinics focusing on...
Pierre Delatte, CTO and co-founder of CISSOID :
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the...
Pierre Drion, business angel :
"For almost 20 years I have been passionate about what is called biotech. This led me to invest in several companies and mainly university spin-offs. In this context, I...
Michel Detheux, CEO Iteos Therapeutics :
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease